John Rex has moved from AstraZeneca to F2G to become the Manchester, UK-based drug discovery firm’s chief medical officer.
He was previously a senior vice president at AZ, where he served as head of infection within its global medicines development unit, and he has been a non-executive director at F2G since 2012.
Ian Nicholson, chief executive officer at F2G, said: “John’s guidance and insight have been instrumental in shaping F2G’s development and regulatory strategy. We are delighted that he is now able to increase his commitment to the company as we progress our new class of antifungal agents into our next clinical trials.”
In his new role Rex will be tasked with helping move F2G’s first-in-class antifungal F901218 through phase II clinical trials.
John Rex said: “I am delighted to have the opportunity to work more closely with F2G as we take the first orotomide antifungal forward through phase II and phase III. Just as with antibacterial resistance, antifungal resistance is a growing threat and F2G’s discovery of an entirely novel class of IV/PO antifungal agent is a key part of the global response to this challenge.”
Prior to joining AstraZeneca in 2003, Rex was professor of medicine at the University of Texas Medical School and has previously served as the industry representative on the US FDA Anti-Infective Drug Advisory Committee.